Xeris Biopharma (NASDAQ:XERS) Insider Sells $42,500.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 5,000 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $8.50, for a total value of $42,500.00. Following the sale, the insider owned 1,361,053 shares of the company’s stock, valued at $11,568,950.50. This trade represents a 0.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.52, for a total value of $235,152.00.
• On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total transaction of $147,900.00.

Xeris Biopharma Stock Up 1.2%

Xeris Biopharma stock traded up $0.10 during trading hours on Wednesday, reaching $8.49. The stock had a trading volume of 1,728,807 shares, compared to its average volume of 1,882,676. The company has a market cap of $1.47 billion, a price-to-earnings ratio of -77.18 and a beta of 0.66. The business’s 50 day moving average price is $7.77 and its 200-day moving average price is $6.80. Xeris Biopharma Holdings, Inc. has a 52 week low of $5.25 and a 52 week high of $10.08. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The firm had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 158.10%. Sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Quantbot Technologies LP purchased a new position in shares of Xeris Biopharma in the second quarter worth $880,000. Landscape Capital Management L.L.C. acquired a new position in shares of Xeris Biopharma in the 2nd quarter valued at $120,000. Ieq Capital LLC purchased a new position in Xeris Biopharma in the 2nd quarter worth $780,000. Allworth Financial LP purchased a new position in Xeris Biopharma in the 2nd quarter worth $34,000. Finally, BlackRock Inc. acquired a new stake in Xeris Biopharma during the 2nd quarter worth about $115,042,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on XERS shares. Weiss Ratings raised shares of Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $10.80.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.